K2 Laboratory recently announced that its two investigational
drugs, Brain Rehabilitation oral solution and Telomerase Inhibitor
oral solution, have successfully obtained National Drug Code (NDC)
numbers.
LOS
ANGELES, July 18, 2024 /PRNewswire/ -- K2
Laboratory recently announced that its two investigational drugs,
Brain Rehabilitation oral solution and Telomerase Inhibitor
oral solution, have successfully obtained National Drug Code (NDC)
numbers. This development marks a new milestone in the research
projects for these two drugs.
Brain Rehabilitation oral solution is an investigational drug
being developed by K2 Laboratory for Alzheimer's disease (AD).
Alzheimer's disease, a complex neurological condition, remains a
key focus area in medical research.
Telomerase Inhibitor oral solution represents K2 Laboratory's
latest research project in the field of cancer studies. Telomerase
is a significant topic in cell biology research, and K2 Laboratory
is exploring its potential applications in cancer research.
Obtaining NDC numbers is a step in the drug development process.
This indicates that these two investigational drugs from K2
Laboratory have completed certain early-stage development phases,
laying the groundwork for potential future studies.
K2 Laboratory stated that the company will continue to advance
the subsequent research and development work for these two
investigational drugs. Additionally, K2 Laboratory plans to
maintain its resource investment and intensify its efforts in
advancing research and development initiatives.
The progress of these two investigational drugs reflects K2
Laboratory's ongoing commitment to pharmaceutical R&D. Industry
insiders view this as a demonstration of the company's efforts in
medical innovation.
It is important to emphasize that these two drugs are currently
still in the research and development phase. Their safety and
efficacy have not been established and will need to be evaluated
through rigorous clinical trials. This press release only reports
on research and development progress and does not make any claims
or implications about potential therapeutic effects.
Related Link:
https://www.k2lt.com/en/
This press release was issued through 24-7PressRelease.com. For
further information, visit http://www.24-7pressrelease.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/k2-laboratory-obtains-ndc-codes-for-two-investigational-drugs-302200396.html
SOURCE K2 Laboratory